FDA Inspection
Octapharma Plasma, Inc.Octapharma Plasma, Inc. – FDA Inspection, Jan 26, 2017
Record Details
This FDA Inspection record concerns Octapharma Plasma, Inc., with an inspection on January 26, 2017, issued by the Center for Biologics Evaluation and Research, covering biologics.
- People
- Julie D. Bringger (FDA Associated Person)
- Valerie J. Grecek-Trinh (Issuing Officer)
View Company Profile
ID · 9366c105-dc61-45df-8892-13ad4d3bdcf4
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1004544
- FDA center
- Biologics
- Project area
- Blood and Blood Products
- Outcome
- Form 483 issued
Other FDA inspections of Octapharma Plasma, Inc.
11| Date | Classification | Office | Project area |
|---|---|---|---|
| September 16, 2026 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| April 17, 2026 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| April 17, 2026 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| January 9, 2026 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| November 21, 2024 | Not classified | Florida District Office |
Other documents for Octapharma Plasma, Inc.
- FDA Inspection 1291170 - 2026-09-16
- FDA Inspection 1315790 - 2026-04-17
- FDA Inspection 1313722 - 2026-04-17
- FDA Inspection 1298618 - 2026-01-09
- FDA Inspection 1255733 - 2024-11-21
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.